Daiichi Sankyo, which has the highest market capitalization, has increased its stock price due to enhartz development for breast cancer with low HER2 expression

The total market value of Daiichi Sankyo reached approximately 6.6 trillion yen (as of 2022/8/4), surpassing Chugai Pharmaceutical, which had been the leader for a long time, to become the top domestic pharmaceutical company. Daiichi Sankyo is focusing on the development of “enhartz” (trastuzumab delxtecan), which is an antibody-drug complex (ADC) using anti-HER2 antibodies, and has obtained approval for diseases such as HER2 positive breast cancer and HER2 positive gastric cancer. At the American Society of Clinical Oncology (ASCO) annual general meeting in 2022/6, an unusual standing ovation occurred in response to the presentation of data from the Enhertz Phase 3 clinical trial targeting HER2 low expression cancer. Along with the growth of Enhertz, the company's stock price remained strong, and reached a year-to-date high of 3662 yen on 7/12.